Viridian’s ‘fast follower’ could challenge Tepezza in thyroid eye disease

Viridian believes an early clinical readout points the way to building a thyroid eye disease franchise that could capture a share of a market in which Horizon’s Tepezza has far outpaced expectations for its launch.

Results announced Monday showed that two infusions of IGF1R-targeting antibody VRDN-001 led to responses in five of six patients with thyroid eye disease at week six in a Phase I/II study, with a mean change in protopsis of 2.4 mm...